
CEO of Microba, Dr. Luke Reid Discusses the Future of the Microbiome for Clinical Use
Dr. Luke Reid, the CEO of Microba discusses the clinical utility and future of microbiome based tests and therapeutics. Dr. Reid speaks to the evolution of the technology, how it is being used in the clinical and research markets today, and the growing importance of the microbiome as an additional biomarker for human health. Key topics discussed are the science behind microbiome testing, how reference standards are being evolved to create comparable tests and databases linking clinical data to outcomes, investment in drug development and changing factors that are influencing it, diagnostic products using the microbiome and their evolution, the company’s partnerships with BioAgilytix, Sonic Healthcare, and SYNLAB, advanced microbiome diagnostics in development by Mainz Biomed for pancreatic cancer, Micronoma for lung cancer and research controversy, and Metabiomics/SOLVD Health for colon cancer, future diagnostic applications of the technology and the role of companion diagnostics using the microbiome, the company’s partnership with Ginkgo Bioworks in autoimmune disease, and the difficulty in reproducing Microba’s diagnostic capabilities.